Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Anatara Lifesciences has provided an update on the evaluation of Detach, which aids in the control of scour in piglets
  • It has been determined that the best way to launch Detach in Australia is via an agreement with an animal health partner
  • Anatara has also further evaluated the regulatory requirements for species other than piglets

Anatara Lifesciences has provided an update on the evaluation of Detach, its non-antibiotic, animal health asset, which aids in the control of scour in piglets.

Scour (diarrhoea) in piglets is an expensive, delimitating and in some cases a life-threatening condition.

Ever since Anatara was listed in 2014 it is aiming to increase survivability and provide health benefits to pre-weaning piglets.

As the company moves forward the Board believes that a substantial market opportunity for Detach exists which will hopefully minimise scour on farms.

Currently, effective and registered alternatives to antibiotics in treating scour are limited. However, zinc oxide was historically used by pig farmers as an alternative to antibiotics but from 2022 high dosage zinc oxide will no longer be able to be used in the European Union.

Detach is a non-antibiotic approach to treat scour and uses bromelain, an extract from pineapple stems.

In October 2018 Anatara announced that The Australian Pesticides and Veterinary Medicines Authority had registered Detach for use in piglets in Australia.

This registering allows the potential fast track product registration within 12 months to South East Asia, in areas such as Vietnam, Myanmar and the Philippines.

However, as other individual countries have varying requirements for regulatory approval many of them require additional field trials.

Following extensive reviews. Anatara has determined the best way to launch Detach into the Australian market is through an agreement with an animal health partner.

Anatara has also further evaluated the regulatory requirements for species other than piglets and has concluded that considerable development work is required for Detach to be approved for use in other species.

“We continue to believe in the value of Anatara’s animal health assets, however, it is clear that further investment is required to realise this,” Anatara CEO Steve Lydeamore.

“It is our intent to achieve success through partnering with multi-national animal health companies.”

Updates will be provided as activities progress.

ANR by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.